Sentence examples for undergo clinical development from inspiring English sources

Crizotinib was the first ALK-TKI to undergo clinical development in ALK-positive advanced NSCLC, in which it has been shown to greatly outperform the best available chemotherapy regimen in either second- or first-line setting.

Results of this study demonstrate that 7-day treatment with telithromycin 800 mg once-daily telithromycin, the first ketolide antibacterial to undergo clinical development, is safe and effective in the treatment of CAP.

Given the above, it would appear that pharmacological inhibition of Hsps can provide therapeutic opportunities in the field of cancer treatment [ 8- 12]; 17- allylamino, 17-demethoxygeldanamycin (17-AAG), the first Hsp90 inhibitor to undergo clinical development, has yielded promising results [ 3, 13].

As a result of the multifaceted Hsp involvement in breast cancer, pharmacological inhibition of Hsps appears to provide therapeutic opportunities in the field of cancer treatment [ 9- 17-allylaminoamino, 17-demethoxygeldanamycin (17-AAG), the first Hsp90 inhibitor to undergo clinical development, has yielded promising results [ 14, 15].

Finally, a brief outline of cocrystals that are undergoing clinical development has also been presented.

Furthermore, all indications are that this upward trend will continue, with a quarter of all new biological products currently undergoing clinical development being antibody based.

Several block copolymer micelle products are currently undergoing clinical development; however, a major challenge in the development and evaluation of such products is identification of the physicochemical properties that affect the properties of the drug product in vivo.

A periodical revision of this document is expected, which will be of particular importance for the use of new anticoagulant drugs currently undergoing clinical development, some of which (edoxaban, betrixaban, and others) are still undergoing a preliminary trial phase.

As a crucial role in physiological and pathological coagulation, thrombin can be considered a very successful drug target because numerous direct thrombin inhibitors, e.g., Hirudin, Bivalirudin, Lepirudin, Desirudin, Argatroban, Melagatran and Dabigatran are in clinical use or undergoing clinical development as antithrombosis agents[57].

Other novel HER2-directed agents are undergoing clinical development.

Not surprisingly, lixisenatide is undergoing clinical development as a combination product with insulin glargine (Lantus®).